Zoetis (NYSE:ZTS – Get Free Report) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $1.85 per share and revenue of $2.5015 billion for the quarter. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.
Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the business posted $1.48 EPS. On average, analysts expect Zoetis to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Zoetis Stock Performance
NYSE:ZTS opened at $77.13 on Tuesday. The stock has a 50 day simple moving average of $76.97 and a 200 day simple moving average of $101.99. The stock has a market cap of $32.33 billion, a P/E ratio of 12.79, a PEG ratio of 1.21 and a beta of 0.73. Zoetis has a 1-year low of $71.47 and a 1-year high of $160.48. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.
Zoetis Announces Dividend
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus dropped their target price on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Morgan Stanley lowered their price target on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 22nd. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Finally, TD Cowen dropped their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $118.33.
Read Our Latest Analysis on Zoetis
Insider Buying and Selling at Zoetis
In other news, Director Michael B. Mccallister purchased 3,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frank A. Damelio acquired 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 11,650 shares of company stock worth $886,384 over the last 90 days. Insiders own 0.22% of the company’s stock.
Hedge Funds Weigh In On Zoetis
Several large investors have recently bought and sold shares of ZTS. Prosperity Bancshares Inc acquired a new stake in Zoetis during the 4th quarter worth approximately $25,000. Intesa Sanpaolo Wealth Management acquired a new position in Zoetis in the 4th quarter valued at approximately $42,000. DV Equities LLC bought a new position in shares of Zoetis during the fourth quarter valued at $77,000. Bellevue Group AG lifted its holdings in shares of Zoetis by 32.7% during the third quarter. Bellevue Group AG now owns 872 shares of the company’s stock worth $128,000 after purchasing an additional 215 shares during the period. Finally, Newbridge Financial Services Group Inc. lifted its holdings in shares of Zoetis by 23.7% during the third quarter. Newbridge Financial Services Group Inc. now owns 1,145 shares of the company’s stock worth $168,000 after purchasing an additional 219 shares during the period. 92.80% of the stock is currently owned by institutional investors.
About Zoetis
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles
- Five stocks we like better than Zoetis
- 3 Drone Stocks That Should Soar After the Summer Slump
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
-JSOL.png){kind=small}
